Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults
Phase II, Randomized, Observer-Blind, Single Center, Controlled Study of Two Doses of Various Formulations of WRAIR Live Attenuated Tetravalent Dengue Vaccine Compared to Placebo Control Administered on 0-6-Month Schedule to Healthy Adults
Sponsor: GlaxoSmithKline
This PHASE2 trial investigates Dengue and is currently completed. GlaxoSmithKline leads this study, which shows 10 recorded versions since 2006 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Mar 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE2
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Nov 2018 — Aug 2019 [monthly]
Completed PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- U.S. Army Medical Research and Development Command
- Walter Reed Army Institute of Research (WRAIR)
For direct contact, visit the study record on ClinicalTrials.gov .